Evidence map›Paper›PMID 42609837›Full record

ArticleIranian journal of basic medical sciences2026

Toktam Dehghani, Seyed Mousalreza Hosseini, Janbibi Dorazehi, Seyedeh Elnaz Nazari, Bahram Memar, Mojtaba Meshkat, Hoorieh Soleimanjahi, Omid Rajabi, Saeid Zibaee, Majid Khazaei and 1 more

Abstract read
In one paragraph

Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Toktam DehghaniDepartment of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Mousalreza HosseiniDepartment of Gastroenterology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Janbibi DorazehiDepartment of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyedeh Elnaz NazariMetabolic Syndrome Research Center, Department of Physiology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
Bahram MemarSurgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mojtaba MeshkatDepartment of Community Medicine, MMS.C. Islamic Azad University, Mashhad, Iran.
Hoorieh SoleimanjahiDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Omid RajabiMedical Chemistry Department, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Saeid ZibaeeDepartment of Research and Development of Biological Products, Agricultural Research, Education and Extension Organization (AREEO),Razi Vaccine and Serum Research Institute, Mashhad, Iran.
Majid KhazaeiMetabolic Syndrome Research Center, Department of Physiology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
Zahra MeshkatAntimicrobial Resistance Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Cervical cancer, the fourth most common malignancy among women, is strongly associated with high-risk human papillomavirus (HPV) infection. Emerging evidence suggests that hydrogen peroxide, alongside standard therapies, may enhance treatment. This study investigated the effects of Imoxide (0.5% hydrogen peroxide compound) and diluted vitamin C on tumor growth in the TC-1 papillomavirus mouse model. Materials and Methods: Cytotoxicity of 3% hydrogen peroxide and 100 mg/ml vitamin C was assessed using the MTT assay on TC-1 cells. Six-week-old female C57BL/6 mice were used to establish TC-1 tumor models in groups by grafting. Mice were divided into seven groups: intratumoral (IT) control, intraperitoneal (IP) control, IP Imoxide, IT Imoxide, cisplatin, IP vitamin C, and IT vitamin C. Tumor size was measured every other day. Histopathological analysis and real-time PCR were conducted to evaluate gene expression (P53, P21, BAX, BCL-2). Results: Dilutions of 10⁻³ and 10⁻⁴ of hydrogen peroxide resulted in cell survival rates of 53.7% and 58.8%, respectively. Imoxide markedly inhibited tumor growth Conclusion: Imoxide substantially suppressed tumor growth in the murine model; however, modulation of apoptosis-related genes was minimal, suggesting that non-apoptotic pathways may contribute to its antitumor effects.

Indexed as

Cervical cancerH2O2Hydrogen peroxideImoxidePapillomavirusVitamin C

Identifiers

PMID42609837
PMCPMC13480705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.